Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Letolizumab Biologics Sequence Review Report 2026: CD40LG Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Letolizumab, an antibody targeting CD40LG.
8 min read
Zampilimab Biologics Sequence Review Report 2026: TGM2 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zampilimab, an antibody targeting TGM2.
Latest Hotspot
8 min read
Vofatamab Biologics Sequence Review Report 2026: FGFR3 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vofatamab, an antibody targeting FGFR3.
Latest Hotspot
8 min read
Tilogotamab Biologics Sequence Review Report 2026: TNFRSF10B Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tilogotamab, an antibody targeting TNFRSF10B.
Latest Hotspot
8 min read
Thanatophoric dysplasia Indication Strategy Report 2026: FGFR3, Trials and Deals
24 July 2026
2026 Thanatophoric dysplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hypochondroplasia Indication Strategy Report 2026: FGFR3, Trials and Deals
24 July 2026
2026 Hypochondroplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Achondroplasia Indication Strategy Report 2026: FGFR3, Trials and Deals
24 July 2026
2026 Achondroplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Cleidocranial dysplasia Indication Strategy Report 2026: RUNX2, Trials and Deals
24 July 2026
2026 Cleidocranial dysplasia strategy: epidemiology, RUNX2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pycnodysostosis Indication Strategy Report 2026: CTSK, Trials and Deals
24 July 2026
2026 Pycnodysostosis strategy: epidemiology, CTSK biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Osteopetrosis Indication Strategy Report 2026: RANKL, Trials and Deals
24 July 2026
2026 Osteopetrosis strategy: epidemiology, RANKL biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Mitochondrial neurogastrointestinal encephalomyopathy Indication Strategy Report 2026: TYMP, Trials and Deals
24 July 2026
2026 Mitochondrial neurogastrointestinal encephalomyopathy strategy: epidemiology, TYMP biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
NARP syndrome Indication Strategy Report 2026: MT-ATP6, Trials and Deals
24 July 2026
2026 NARP syndrome strategy: epidemiology, MT-ATP6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…